Baxter International (NYSE:BAX) Given New $27.00 Price Target at Barclays

Baxter International (NYSE:BAX) had its price target lifted by Barclays from $25.00 to $27.00 in a research note released on Friday,MarketScreener reports.

Several other equities research analysts have also weighed in on the company. Zacks Research lowered Baxter International from a “hold” rating to a “strong sell” rating in a research note on Friday, April 24th. Evercore reduced their price objective on Baxter International from $23.00 to $22.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Weiss Ratings reissued a “sell (d)” rating on shares of Baxter International in a research note on Wednesday, January 21st. The Goldman Sachs Group reduced their price objective on Baxter International from $21.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, February 13th. Finally, Citigroup reduced their price objective on Baxter International from $21.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, March 11th. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $19.91.

Baxter International Price Performance

Shares of BAX stock traded down $0.33 during mid-day trading on Friday, hitting $17.26. 10,872,013 shares of the stock traded hands, compared to its average volume of 7,258,698. Baxter International has a twelve month low of $15.73 and a twelve month high of $32.68. The firm has a market cap of $8.91 billion, a price-to-earnings ratio of -9.33, a price-to-earnings-growth ratio of 1.24 and a beta of 0.62. The company’s 50-day simple moving average is $17.92 and its 200-day simple moving average is $19.18. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.56 and a current ratio of 2.31.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.05. Baxter International had a positive return on equity of 15.65% and a negative net margin of 9.70%.The company had revenue of $2.70 billion for the quarter, compared to analysts’ expectations of $2.62 billion. During the same period last year, the firm earned $0.62 EPS. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. As a group, equities research analysts expect that Baxter International will post 1.91 earnings per share for the current year.

Baxter International Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Friday, May 29th will be given a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, May 29th. Baxter International’s dividend payout ratio (DPR) is -2.16%.

Institutional Trading of Baxter International

Several hedge funds and other institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC boosted its position in shares of Baxter International by 14.4% in the third quarter. EverSource Wealth Advisors LLC now owns 5,448 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 686 shares during the period. Covestor Ltd boosted its position in shares of Baxter International by 9.5% in the fourth quarter. Covestor Ltd now owns 8,014 shares of the medical instruments supplier’s stock worth $153,000 after buying an additional 695 shares during the period. Bruce G. Allen Investments LLC boosted its position in shares of Baxter International by 22.8% in the fourth quarter. Bruce G. Allen Investments LLC now owns 4,452 shares of the medical instruments supplier’s stock worth $85,000 after buying an additional 827 shares during the period. Jump Financial LLC boosted its position in shares of Baxter International by 5.7% in the fourth quarter. Jump Financial LLC now owns 15,968 shares of the medical instruments supplier’s stock worth $305,000 after buying an additional 854 shares during the period. Finally, Nicholas Hoffman & Company LLC. boosted its position in shares of Baxter International by 2.1% in the fourth quarter. Nicholas Hoffman & Company LLC. now owns 46,913 shares of the medical instruments supplier’s stock worth $897,000 after buying an additional 943 shares during the period. Institutional investors and hedge funds own 90.19% of the company’s stock.

Trending Headlines about Baxter International

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Q1 beat on revenue and EPS — Baxter reported $0.36 EPS vs. consensus $0.31 and $2.70B in revenue (vs. $2.62B expected); top-line growth was driven by strong demand in its medical products & therapies unit. Baxter beats quarterly expectations on strong demand for medical devices
• Positive Sentiment: Overseas sales and segment strength supported the beat and were singled out on the call/presentation, which helped push shares higher initially. Baxter International Inc. 2026 Q1 – Results – Earnings Call Presentation
• Neutral Sentiment: Management reiterated its 2026 growth views and emphasized execution improvements—this supports forward confidence but may not be enough to offset near-term margin concerns. Baxter Posts 1Q Loss, Backs 2026 Growth Views
• Neutral Sentiment: Dividend update: Baxter declared a token quarterly dividend of $0.01 per share (annualized yield ~0.2%); modest cash return that is unlikely to drive significant share moves. (No link)
• Neutral Sentiment: Detailed earnings call transcript and slide deck are available for investors who want granular guidance and margin commentary. Baxter International Inc. (BAX) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Margins contracted and net income metrics remain weak — EPS declined year-over-year (from $0.62 to $0.36) and commentary noted margin pressure, which caps enthusiasm despite the beat. BAX Stock Gains on Q1 Earnings & Sales Beat, Margins Contract
• Negative Sentiment: Evercore cut its price target for BAX (while keeping an Outperform rating), signaling analyst caution and likely weighing on the stock. Evercore Cuts Baxter (BAX) Price Target, Keeps Outperform Rating

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.